Suggestions
Samir Khan
Health Innovation Catalyst - Market Access & Pricing Expert - Global Impact-maker
Samir Khan is a distinguished health innovation strategist and global market access professional with over eight years of experience in the Life Sciences and Healthcare sector.
He is known for his expertise in developing user-centric design, evidence-based, and commercial access solutions for public and corporate leaders investing in areas such as preventative and precision medicine, diagnostics, AI, digital therapeutics, and system transformation.
Samir has served as a strategic access advisor to investors, top global Life Sciences and Healthcare businesses, NHS England, and numerous start-ups, offering guidance on international market access strategies, payer engagement, value-based pricing, and risk-sharing agreements across various healthcare fields including oncology, rare diseases, mental health, and chronic inflammatory indications.
His notable achievements include being a Panel Reviewer for the NHSX-NIHR's AI Award in 2020 (£250 million) and holding strategic advisory roles at renowned organizations like Jiva.ai, Oxford Immune Algorithmics, Aya Technologies, and Unbounded Future.
In terms of education, Samir holds an MSc in Biochemistry (2.1) from the Department of Biochemistry at Aligarh University, a Doctor of Philosophy in Molecular Pharmacology from the University of Cambridge under the Bill and Melinda Gates Trust Scholarship, and a BSc Honors in Biochemistry (2.1) from Aligarh University.
Throughout his career, Samir Khan has been associated with various organizations in key roles such as Co-Founder & CEO at Lighthouse Innovations Ltd, Programme Advisor for Market Access & Pricing at TheHill, Start-up Mentor at P4 Precision Medicine Accelerator, Global Access & Pricing Advisor at KQ Labs, and Business Strategy & Market Access Manager at Oxford Academic Health Science Network (Oxford AHSN).
He has also contributed his expertise as a Consultant in Market Access and Healthcare at Ipsos, Global Market Access Consultant at GfK, Operations and Commercial Strategy at New Medicine Partners, Senior Analyst at Xyntéo, Associate Consultant focusing on Market Access Strategy & Commercial Effectiveness at Pope Woodhead & Associates Ltd, Medicines & Analytics Intern at The Centre for Sustainable Healthcare, Business Development Consultant at Healx3, Associate Director at Ekstasy, and Industrial Post-Doctoral Research Scientist at Heptares.
Samir Khan's academic journey includes serving as President at Darwin College, Cambridge, a PhD Scholar under the Bill & Melinda Gates fellowship in Pharmacology at the University of Cambridge, and as a Junior Research Fellow at ICGEB.
Highlights
To all my friends, old and new, on LinkedIn – a heartfelt thank you for your immediate notice, ideas, and wonderful support. We are now in a much better place with options for Zahra Khan's treatment.
Zahra’s case is a powerful reminder of the importance of ‘access to quality healthcare’ and the incredible impact of #empathy and #collaboration on platforms like #LinkedIn. Human disease and the need for treatment and care is a shared experience across families, homes, and workplaces for all of us. This universal pain-point highlights our collective willingness to solve problems and share insights beyond the barriers of system, commerce, and jurisdiction.
A week later, after receiving hundreds of messages, recordings, and emails, here’s what I learned (along with Zahra Khan and Babar Shaikh):
-
The Power of Patient Stories: Nothing is more powerful than the story of lived experiences from survivors of rare or late-stage cancers. Their user experience, confidence, and outcomes (PROs) on therapy side effects (e.g., ADCs, PARP inhibitors, DCTs, immunotherapy, and chemotherapy), consultation consequences, advocacy networks, and lifestyle change are incredible and empowering. Thank you, Isabel Lokody, Julie Holmwood 🧞♀️ Holmwood, Pilar Fernandez Hermida, Gowyn G, Swetang Khambhatwala, and Paul de Gruchy Gaudin, for sharing your insights.
-
Importance of Local Access and Experience: Time and location are critical in a patient’s situation and severity. World-class clinicians, companion diagnostics, or curative therapies trialed across the globe can be limited by eligibility, affordability, access, and turn-around barriers. Medical tourism, wellness, and recovery present great opportunities for the NHS and its cancer care ecosystem. It starts with willing specialists and clinical trial navigators engaging with worldwide patients, balancing their time between local patient backlogs and stage-critical patients globally. Thanks, Peter Hall, Chris Teale, Dr Nina Fuller-Shavel, HCA Healthcare UK, Ritesh Patel, David Britton, Massive Bio, and Hazel Dawson, for your valuable insights and open-minded advice.
-
Real-World Data and Evidence Standards: In the globalised world of healthcare, real-world data (RWD) and evidence standards are paramount. Life-changing tests or therapies face approval and access challenges due to varying safety-efficacy across populations. Procedures like dendritic cell therapy (DCT) are gaining popularity due to fewer side effects and flexible business models. However, clinical guidelines and health economic research are lacking, despite availability across the world. In South Asia, pre-procurement regulatory evidence seems to be a token, with real-world data (RWD) missing. Aggregating RWD from public and private institutions that is open for research and global partnerships can significantly improve access to clinical studies, evidence local innovative therapies, and speed up access to game-changing innovation worldwide.
URGENT ADVICE NEEDED: My cousin Zahra Khan, a brave young girl, is facing an incredibly tough battle. Diagnosed with BRCA1, Triple Negative Stage 2 breast cancer at 30, she fought through chemotherapy, immunotherapy, double mastectomy, and radiotherapy, showing no signs of lesions by August 2022. Unfortunately, she has recently relapsed (June 2024). Cancer lesions were found in her spine and two nodes in her neck, now diagnosed as Stage 4 Triple Negative Breast Cancer. We urgently need your support and guidance. If you have any insights on clinical trials, therapies, or treatment locations that could assist Zahra, please comment below or DM me. Your help could make a world of difference. Thank you! 🙏
#CancerSupport #ClinicalTrials #BreastCancer #BRCA1 #TripleNegative
